{
    "Title": "Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening",
    "URL": "https://doi.org/10.1371/journal.pntd.0007126",
    "Published": "January 28, 2019",
    "Subject_Areas": [
        "Mycobacterium ulcerans",
        "Buruli ulcer",
        "Drug interactions",
        "Drug therapy",
        "Tuberculosis",
        "Mycobacterium tuberculosis",
        "Streptomycin",
        "Mouse models"
    ],
    "Authors": {
        "María Pilar Arenaz-Callao": [
            "Research & Development Agency of Aragon (ARAID) Foundation, Zaragoza, Spain",
            "Global Health R&D, GlaxoSmithKline, Tres Cantos, Madrid, Spain"
        ],
        "Rubén González del Río": [
            "Global Health R&D, GlaxoSmithKline, Tres Cantos, Madrid, Spain"
        ],
        "Ainhoa Lucía Quintana": [
            "Mycobacterial Genetics Group. Department of Microbiology, Preventive Medicine and Public Health. Faculty of Medicine, University of Zaragoza, Zaragoza, Spain"
        ],
        "Charles J. Thompson": [
            "Department of Microbiology and Immunology, University of British Columbia, Vancouver, B.C. Canada"
        ],
        "Alfonso Mendoza-Losana": [
            "Global Health R&D, GlaxoSmithKline, Tres Cantos, Madrid, Spain"
        ],
        "Santiago Ramón-García": [
            "Research & Development Agency of Aragon (ARAID) Foundation, Zaragoza, Spain",
            "Global Health R&D, GlaxoSmithKline, Tres Cantos, Madrid, Spain",
            "Mycobacterial Genetics Group. Department of Microbiology, Preventive Medicine and Public Health. Faculty of Medicine, University of Zaragoza, Zaragoza, Spain",
            "Department of Microbiology and Immunology, University of British Columbia, Vancouver, B.C. Canada"
        ]
    }
}